John P. Hamill is CFO at Aprea Therapeutics, Inc. (APRE). They have made 10 open-market trades across 3 companies since 2019, most recently 2026-03-31.
CIK 0001716213
10 open-market purchases totalling $42K since 2019, never a sale. Across 10 scored buys the stock is down 15.7% at ninety days, and 18.2 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| TRVN | 87,750 | $219K |
| APRE | 30,978 | $18K |
| WINT | 72,800 | $7K |
| Total | $245K |
Shares reported on the most recent Form 4, priced at the 2026-04-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 70% | 40% | 10% |
| Avg Move | +2.9% | -0.7% | -15.7% |
| Alpha | +1.9% | -2.7% | -18.2% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APRE | BUY | 2026-01-30 | 2026-02-02 | $0.89 | $5K | -16.5% | +28.3% | +18.9% |
| APRE | BUY | 2025-12-10 | 2025-12-11 | $1.17 | $6K | +0.2% | -3.2% | -17.2% |
| APRE | BUY | 2024-10-11 | 2024-10-16 | $2.46 | $123 | +13.8% | -13.6% | -3.7% |
| APRE | BUY | 2024-10-10 | 2024-10-15 | $2.61 | $1K | -5.6% | -22.5% | -20.8% |
| APRE | BUY | 2024-03-13 | 2024-03-14 | $7.29 | $7K | +5.9% | +5.5% | -22.7% |
| WINT | BUY | 2022-07-26 | 2022-07-26 | $0.37 | $1K | +7.9% | +26.1% | -47.4% |
| WINT | BUY | 2021-04-16 | 2021-04-19 | $2.07 | $2K | +4.5% | -18.4% | -17.9% |
| WINT | BUY | 2021-03-25 | 2021-03-25 | $3.25 | $5K | +2.0% | -1.2% | -8.6% |
| WINT | BUY | 2020-10-07 | 2020-10-09 | $5.27 | $5K | +22.5% | +0.8% | -10.4% |
| TRVN | BUY | 2019-05-31 | 2019-06-04 | $1.16 | $9K | -6.2% | -8.8% | -27.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.